Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ).
Shanghai Henlius Biotech, Inc. reported that its annual general meeting, held in Shanghai on 19 May 2026, met quorum with shareholders or authorised representatives holding approximately 47.85% of voting shares present. All directors attended, and the meeting was conducted in compliance with PRC company law and the firm’s articles of association, with an independent scrutineer overseeing the vote tabulation.
Shareholders unanimously approved all ordinary resolutions, including the 2025 annual report, the board and board of supervisors’ work reports, the final accounts, and the 2025 profit distribution proposal. The 100% support across all resolutions signals broad shareholder confidence in the company’s governance, financial reporting, and capital allocation, and clears the way for implementation of its 2025 profit distribution plan.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a PRC-based biopharmaceutical company listed in Hong Kong, engaged in the development and commercialisation of biologic drugs. The company operates through both unlisted domestic shares and H shares, reflecting a focus on both mainland China and international capital markets.
Average Trading Volume: 931,143
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.69B
Find detailed analytics on 2696 stock on TipRanks’ Stock Analysis page.